Neurent Medical has successfully raised €62.5 million in an oversubscribed Series C financing round, led by MVM Partners and Sofinnova Partners, to accelerate the commercial expansion and clinical validation of its innovative NEUROMARK treatment for chronic rhinitis.

Information on the target

Neurent Medical is a pioneering company based in Galway, Ireland, focused on transforming the treatment landscape for chronic inflammatory sinonasal diseases. The company has developed NEUROMARK®, an innovative, minimally invasive solution designed to treat chronic rhinitis, a condition that affects millions globally. NEUROMARK utilizes proprietary Impedance Controlled Radiofrequency technology to target the overactive posterior nasal nerves, providing a differentiated and durable treatment option that addresses the root cause of the symptoms rather than merely managing them.

Recently, Neurent Medical successfully closed its oversubscribed Series C financing round, raising €62.5 million ($74 million). This funding will be instrumental in driving the company's commercial expansion, broadening clinical evidence, and advancing its product and indication pipeline, ultimately aiming to bring NEUROMARK to a wider patient and physician audience.

Industry overview in the target’s specific country

The healthcare industry in Ireland has been experiencing significant growth, particularly in the medtech sector, which has become a focal point for innovation and investment. Ireland is home to a robust ecosystem of medical technology compani